CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26713
Abstract: To the Editor: Acute lymphoblastic leukemia (ALL) bearing the KMT2Arearrangement is a high-risk genomic subgroup, characterized by chemotherapy-resistance and a propensity for rapid relapse with reported 5-year overall survival of less than 20%. Unique in… read more here.
Keywords: kmt2a rearranged; directed immunotherapy; leukemia; cd19 directed ... See more keywords
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004128
Abstract: Background Waldenström macroglobulinemia (WM) is an incurable disease and, while treatable, can develop resistance to available therapies and be fatal. Chimeric antigen receptor (CAR) T cell therapy directed against the CD19 antigen has demonstrated efficacy… read more here.
Keywords: cell; car therapy; therapy; car ... See more keywords
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021012634
Abstract: CD19-directed chimeric antigen receptor-modified T cells (CAR T cells) achieve durable remissions in about 30-40% of relapsed/refractory large B-cell lymphomas. T cell exhaustion and/or an immunosuppressive tumor-microenvironment may contribute to CAR T-cell failure. Pembrolizumab, an… read more here.
Keywords: car cell; cd19 directed; pembrolizumab; therapy ... See more keywords
CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014840
Abstract: Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered… read more here.
Keywords: cell; cd34 cd19; cd19 directed; cd19 cd22 ... See more keywords
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005747
Abstract: Key Points CHIP is frequently observed in patients with r/r lymphoma undergoing CD19-directed CAR T-cell therapy. CHIP does not negatively influence the outcome of CD19-directed CAR T-cell therapy. read more here.
Keywords: cd19 directed; chip; directed car; car cell ... See more keywords
Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2022-0145
Abstract: Aim: Comprehensively characterize the cardiotoxicity of CD19-directed chimeric antigen receptor T-cell (CAR-T) products. Materials & methods: Data between 2017 and 2021 in the US FDA's Adverse Event Reporting System database were utilized. Disproportionality was measured using reporting… read more here.
Keywords: directed chimeric; antigen receptor; receptor cell; chimeric antigen ... See more keywords